A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy

HIV Medicine

Volumn 11, Issue 1, 2010, Pages 54-63

  Hung, C C ^a,b   Chang, S Y ^b   Su, C T ^b   Chen, Y Y ^b   Chang, S F ^b   Yang, C Y ^b   Liu, W C ^a   Wu, C H ^a   Chang, S C ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antibody response; HIV; Pneumococcal polysaccharide vaccine; Pneumococcal vaccination; Streptococcus pneumoniae

Indexed keywords

ANTIRETROVIRUS AGENT; PNEUMOCOCCUS VACCINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; TREATMENT RESPONSE; VACCINATION;

ADULT; AGED; ANTIBODIES, BACTERIAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RNA, VIRAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 72549104417     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00744.x     Document Type: Article

References (40)

1. Redd SC, Rutherford GW, Sande MA. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990, 162:1012-1017.
2. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000, 132:182-190.
3. Jordano Q, Falco V, Almirante B. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004, 38:1623-1628.
4. Heffernan RT, Barrett NL, Gallagher KM. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005, 191:2038-2045.
5. Rodriguez-Barradas MC, Goulet J, Brown S. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis 2008, 46:1093-1100.
6. Grau I, Pallares R, Tubau F. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005, 165:1533-1540.
7. Saindou M, Chidiac C, Miailhes P. Pneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods. HIV Med 2008, 9:203-207.
8. Breiman RF, Keller DW, Phelan MA. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000, 160:2633-2638.
9. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001, 32:794-800.
10. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004, 22:2006-2012.
11. Penaranda M, Falco V, Payeras A. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis 2007, 45:e82-e87.
12. Teshale EH, Hanson D, Flannery B. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998-2003. Vaccine 2008, 26:5830-5834.
13. 2008, 1-289. Adult Prevention and Treatment of Opportunistic Infections Guidelines Working Group., Guidelines for prevention and treatment of opportunistic infections in HIV-1-infected adults and adolescents. U.S. Department of Health and Human Services
14. Ballet JJ, Sulcebe G, Couderc LJ. Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. Clin Exp Immunol 1987, 68:479-487.
15. Janoff EN, Douglas JM, Gabriel M. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. J Infect Dis 1988, 158:983-990.
16. Opravil M, Fierz W, Matter L, Blaser J, Luthy R. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol 1991, 84:185-189.
17. Rodriguez-Barradas MC, Musher DM, Lahart C. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis 1992, 165:553-556.
18. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4 lymphocytes. AIDS (London, UK) 1994, 8:469-476.
19. Carson PJ, Schut RL, Simpson ML, O'Brien J, Janoff EN. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. J Infect Dis 1995, 172:340-345.
20. Weiss PJ, Wallace MR, Oldfield EC, O'Brien J, Janoff EN. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine. J Infect Dis 1995, 171:1217-1222.
21. Mascart-Lemone F, Gerard M, Libin M. Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine. J Infect Dis 1995, 172:1253-1260.
22. Ahmed A, Li J, Shiloach Y, Robbins JB, Szu SC. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. J Infect Dis 2006, 193:515-521.
23. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 1999, 18:524-530.
24. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 2000, 19:886-894.
25. Amendola A, Tanzi E, Zappa A. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected former drug users. Vaccine 2002, 20:3720-3724.
26. Rodriguez-Barradas MC, Alexandraki I, Nazir T. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003, 37:438-447.
27. Falco V, Jordano Q, Cruz MJ. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine 2006, 24:2567-2574.
28. Plikaytis BD, Goldblatt D, Frasch CE. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J Clin Microbiol 2000, 38:2043-2050.
29. Siber GR, Chang I, Baker S. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007, 25:3816-3826.
30. Huang KL, Ruben FL, Rinaldo CR, Kingsley L, Lyter DW, Ho M. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. JAMA 1987, 257:2047-2050.
31. Klein RS, Selwyn PA, Maude D, Pollard C, Freeman K, Schiffman G. Response to pneumococcal vaccine among asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with human immunodeficiency virus. J Infect Dis 1989, 160:826-831.
32. Glaser JB, Volpe S, Aguirre A, Simpkins H, Schiffman G. Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex. J Infect Dis 1991, 164:761-764.
33. Janoff EN, O'Brien J, Thompson P. Streptococcus pneumoniae colonization, bacteremia, and immune response among persons with human immunodeficiency virus infection. J Infect Dis 1993, 167:49-56.
34. Vandenbruaene M, Colebunders R, Mascart-Lemone F. Equal IgG antibody response to pneumococcal vaccination in all stages of human immunodeficiency virus disease. J Infect Dis 1995, 172:551-553.
35. Nielsen H, Kvinesdal B, Benfield TL, Lundgren JD, Konradsen HB. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis 1998, 30:597-601.
36. Subramaniam KS, Segal R, Lyles RH, Rodriguez-Barradas MC, Pirofski LA. Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J Infect Dis 2003, 187:758-768.
37. Feikin DR, Elie CM, Goetz MB. Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults. Clin Diag Lab Immunol 2004, 11:137-141.
38. Lesprit P, Pedrono G, Molina JM. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS (London, UK) 2007, 21:2425-2434.
39. Moir S, Ogwaro KM, Malaspina A. Perturbations in B cell responsiveness to CD4 T cell help in HIV-infected individuals. Proc Natl Acad Sci USA 2003, 100:6057-6062.
40. Moir S, Ho J, Malaspina A. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 2008, 205:1797-1805.